Troy Ignelzi
Director/Board Member bij ABIVAX
Profiel
Troy A.
Ignelzi is currently the Chairman at Vedanta Biosciences, Inc. and the Director at Abivax SA. Previously, he served as an Independent Director at CinCor Pharma, Inc. from 2021 to 2023.
He was also the Vice President-Business Development at Esperion Therapeutics, Inc. from 2009 to 2013 and the VP-Business Development & Strategic Planning at InSys Therapeutics, Inc. from 2007 to 2009.
Additionally, he held the position of Chief Financial Officer at Juventas Therapeutics, Inc. from 2014 to 2016, Chief Financial Officer at Karuna Therapeutics, Inc. from 2019 to 2023, and Chief Financial & Accounting Officer at scPharmaceuticals, Inc. from 2016 to 2019.
He was the Senior VP-Operations & Business Development at PharmaLex GmbH from 2013 to 2014.
Mr. Ignelzi obtained his undergraduate degree from Ferris State University (Michigan).
Actieve functies van Troy Ignelzi
Bedrijven | Functie | Begin |
---|---|---|
ABIVAX | Director/Board Member | 11-07-2023 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Chairman | - |
Eerdere bekende functies van Troy Ignelzi
Bedrijven | Functie | Einde |
---|---|---|
KARA THER | Director of Finance/CFO | 29-09-2023 |
CINCOR PHARMA, INC. | Director/Board Member | 24-02-2023 |
SCPHARMACEUTICALS INC. | Director of Finance/CFO | 28-02-2019 |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | Director of Finance/CFO | 01-02-2016 |
PharmaLex GmbH
PharmaLex GmbH Packaged SoftwareTechnology Services PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany. | Chief Operating Officer | 01-10-2014 |
Opleiding van Troy Ignelzi
Ferris State University (Michigan) | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ESPERION THERAPEUTICS, INC. | Health Technology |
SCPHARMACEUTICALS INC. | Health Technology |
ABIVAX | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Health Technology |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | Health Services |
Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
PharmaLex GmbH
PharmaLex GmbH Packaged SoftwareTechnology Services PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany. | Technology Services |
CinCor Pharma, Inc.
CinCor Pharma, Inc. Pharmaceuticals: MajorHealth Technology CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA. | Health Technology |